This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kridel, S. J. Articles by Smith, J. W. Search for Related Content PubMed PubMed Citation Articles by Kridel, S. J. Articles by Smith, J. W.

Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity

¹ Cancer Research Center, The Burnham Institute, and ² Activx Biosciences, La Jolla, California

One of the fundamental principles of pharmacology is that most drugs have side effects. Although considerable attention is paid to detrimental side effects, drugs can also have beneficial side effects. Given the time and expense of drug development, it would be particularly exciting if a systematic method could be applied to reveal all of the activities, including the unappreciated actions, of a potential drug. The present study takes the first step along this path. An activity-based proteomics strategy was used to simultaneously identify targets and screen for their inhibitors in prostate cancer. Orlistat, a Food and Drug Administration-approved drug used for treating obesity, was included in this screen. Surprisingly, we find a new molecular target and a potential new application for Orlistat. Orlistat is a novel inhibitor of the thioesterase domain of fatty acid synthase, an enzyme strongly linked to tumor progression. By virtue of its ability to inhibit fatty acid synthase, Orlistat halts tumor cell proliferation, induces tumor cell apoptosis, and inhibits the growth of PC-3 tumors in nude mice.

This article has been cited by other articles:

				T. Migita, T. Narita, K. Nomura, E. Miyagi, F. Inazuka, M. Matsuura, M. Ushijima, T. Mashima, H. Seimiya, Y. Satoh, et al. ATP Citrate Lyase: Activation and Therapeutic Implications in Non-Small Cell Lung Cancer Cancer Res., October 15, 2008; 68(20): 8547 - 8554. [Abstract] [Full Text] [PDF]

				M. Prentki and S. R. M. Madiraju Glycerolipid Metabolism and Signaling in Health and Disease Endocr. Rev., October 1, 2008; 29(6): 647 - 676. [Abstract] [Full Text] [PDF]

				Y. Zhan, N. Ginanni, M. R. Tota, M. Wu, N. W. Bays, V. M. Richon, N. E. Kohl, E. S. Bachman, P. R. Strack, and S. Krauss Control of Cell Growth and Survival by Enzymes of the Fatty Acid Synthesis Pathway in HCT-116 Colon Cancer Cells Clin. Cancer Res., September 15, 2008; 14(18): 5735 - 5742. [Abstract] [Full Text] [PDF]

				J. Ross, A. M. Najjar, M. Sankaranarayanapillai, W. P. Tong, K. Kaluarachchi, and S. M. Ronen Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine Mol. Cancer Ther., August 1, 2008; 7(8): 2556 - 2565. [Abstract] [Full Text] [PDF]

				C. A. Haynes, J. C. Allegood, K. Sims, E. W. Wang, M. C. Sullards, and A. H. Merrill Jr. Quantitation of fatty acyl-coenzyme As in mammalian cells by liquid chromatography-electrospray ionization tandem mass spectrometry J. Lipid Res., May 1, 2008; 49(5): 1113 - 1125. [Abstract] [Full Text] [PDF]

				H. Liu, Y. Liu, and J.-T. Zhang A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction Mol. Cancer Ther., February 1, 2008; 7(2): 263 - 270. [Abstract] [Full Text] [PDF]

				A. L. Vavere, S. J. Kridel, F. B. Wheeler, and J. S. Lewis 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer J. Nucl. Med., February 1, 2008; 49(2): 327 - 334. [Abstract] [Full Text] [PDF]

				H. Orita, J. Coulter, C. Lemmon, E. Tully, A. Vadlamudi, S. M. Medghalchi, F. P. Kuhajda, and E. Gabrielson Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment Clin. Cancer Res., December 1, 2007; 13(23): 7139 - 7145. [Abstract] [Full Text] [PDF]

				A. Beckers, S. Organe, L. Timmermans, K. Scheys, A. Peeters, K. Brusselmans, G. Verhoeven, and J. V. Swinnen Chemical Inhibition of Acetyl-CoA Carboxylase Induces Growth Arrest and Cytotoxicity Selectively in Cancer Cells Cancer Res., September 1, 2007; 67(17): 8180 - 8187. [Abstract] [Full Text] [PDF]

				R. D. Richardson and J. W. Smith Novel antagonists of the thioesterase domain of human fatty acid synthase Mol. Cancer Ther., July 1, 2007; 6(7): 2120 - 2126. [Abstract] [Full Text] [PDF]

				J. G. Pan and T. W. Mak Metabolic Targeting as an Anticancer Strategy: Dawn of a New Era? Sci. Signal., April 10, 2007; 2007(381): pe14 - pe14. [Abstract] [Full Text] [PDF]

				J. L. Little, F. B. Wheeler, D. R. Fels, C. Koumenis, and S. J. Kridel Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor Cells Cancer Res., February 1, 2007; 67(3): 1262 - 1269. [Abstract] [Full Text] [PDF]

				C. D. Browne, E. J. Hindmarsh, and J. W. Smith Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor FASEB J, October 1, 2006; 20(12): 2027 - 2035. [Abstract] [Full Text] [PDF]

				W. B. Kinlaw, J. L. Quinn, W. A. Wells, C. Roser-Jones, and J. T. Moncur Spot 14: A Marker of Aggressive Breast Cancer and a Potential Therapeutic Target Endocrinology, September 1, 2006; 147(9): 4048 - 4055. [Abstract] [Full Text] [PDF]

				M. A. Madsen, E. I. Deryugina, S. Niessen, B. F. Cravatt, and J. P. Quigley Activity-based Protein Profiling Implicates Urokinase Activation as a Key Step in Human Fibrosarcoma Intravasation J. Biol. Chem., June 9, 2006; 281(23): 15997 - 16005. [Abstract] [Full Text] [PDF]

				X. Liu, Y. Shi, V. L. Giranda, and Y. Luo Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol. Cancer Ther., March 1, 2006; 5(3): 494 - 501. [Abstract] [Full Text] [PDF]

				R.-C. Jiang, H.-D. Qin, M.-S. Zeng, W. Huang, B.-J. Feng, F. Zhang, H.-K. Chen, W.-H. Jia, L.-Z. Chen, Q.-S. Feng, et al. A Functional Variant in the Transcriptional Regulatory Region of Gene LOC344967 Cosegregates with Disease Phenotype in Familial Nasopharyngeal Carcinoma Cancer Res., January 15, 2006; 66(2): 693 - 700. [Abstract] [Full Text] [PDF]

				K. Brusselmans, E. De Schrijver, G. Verhoeven, and J. V. Swinnen RNA Interference-Mediated Silencing of the Acetyl-CoA-Carboxylase-{alpha} Gene Induces Growth Inhibition and Apoptosis of Prostate Cancer Cells Cancer Res., August 1, 2005; 65(15): 6719 - 6725. [Abstract] [Full Text] [PDF]

				J. A. Menendez, L. Vellon, and R. Lupu Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene Ann. Onc., August 1, 2005; 16(8): 1253 - 1267. [Abstract] [Full Text] [PDF]

				J. A. Menendez, L. Vellon, and R. Lupu Orlistat: From Antiobesity Drug to Anticancer Agent in Her-2/neu (erbB-2)-Overexpressing Gastrointestinal Tumors? Experimental Biology and Medicine, March 1, 2005; 230(3): 151 - 154. [Full Text] [PDF]

				B. Chakravarty, Z. Gu, S. S. Chirala, S. J. Wakil, and F. A. Quiocho Human fatty acid synthase: Structure and substrate selectivity of the thioesterase domain PNAS, November 2, 2004; 101(44): 15567 - 15572. [Abstract] [Full Text] [PDF]

				L. M. Knowles, F. Axelrod, C. D. Browne, and J. W. Smith A Fatty Acid Synthase Blockade Induces Tumor Cell-cycle Arrest by Down-regulating Skp2 J. Biol. Chem., July 16, 2004; 279(29): 30540 - 30545. [Abstract] [Full Text] [PDF]